Reuters: World’s largest generic drugmaker earned 60 cents per diluted share, down from 94 cents a year earlier; says on track to cut $3 billion in costs by the end 2019
Reductions will come across all business units and regions; the firm plans to invest in innovation for its key products and expand sales efforts in key markets
In 2018, the Jerusalem University's tech transfer arm struck 25 licensing agreements in the field of cannabis, accounting for 10% of total licensing volume that year
Recent comments